Segall Bryant & Hamill LLC Has $12.57 Million Stake in iRhythm Technologies, Inc. (NASDAQ:IRTC)

Segall Bryant & Hamill LLC boosted its holdings in iRhythm Technologies, Inc. (NASDAQ:IRTC - Free Report) by 5.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 139,391 shares of the company's stock after acquiring an additional 6,789 shares during the period. Segall Bryant & Hamill LLC owned about 0.45% of iRhythm Technologies worth $12,569,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. R Squared Ltd acquired a new position in iRhythm Technologies during the 4th quarter valued at approximately $45,000. Van ECK Associates Corp lifted its stake in iRhythm Technologies by 41.3% in the fourth quarter. Van ECK Associates Corp now owns 554 shares of the company's stock valued at $50,000 after buying an additional 162 shares during the last quarter. Quarry LP acquired a new position in shares of iRhythm Technologies during the third quarter valued at $59,000. Nisa Investment Advisors LLC grew its position in shares of iRhythm Technologies by 166.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,037 shares of the company's stock worth $94,000 after acquiring an additional 648 shares during the last quarter. Finally, KBC Group NV grew its position in shares of iRhythm Technologies by 45.1% during the fourth quarter. KBC Group NV now owns 1,319 shares of the company's stock worth $119,000 after acquiring an additional 410 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have commented on IRTC. Oppenheimer boosted their price objective on iRhythm Technologies from $105.00 to $120.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 8th. StockNews.com raised iRhythm Technologies from a "sell" rating to a "hold" rating in a research note on Monday, February 24th. Needham & Company LLC boosted their price target on iRhythm Technologies from $125.00 to $138.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Canaccord Genuity Group raised their price target on iRhythm Technologies from $125.00 to $152.00 and gave the company a "buy" rating in a report on Monday, December 9th. Finally, Truist Financial upped their price objective on shares of iRhythm Technologies from $111.00 to $145.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $119.73.

iRhythm Technologies Price Performance

Shares of NASDAQ:IRTC traded down $1.11 during trading hours on Friday, hitting $105.00. 233,597 shares of the company's stock traded hands, compared to its average volume of 461,972. The company's fifty day simple moving average is $108.09 and its two-hundred day simple moving average is $90.16. The company has a market cap of $3.30 billion, a price-to-earnings ratio of -28.85 and a beta of 1.36. The company has a debt-to-equity ratio of 9.00, a quick ratio of 6.12 and a current ratio of 6.27. iRhythm Technologies, Inc. has a 52 week low of $55.92 and a 52 week high of $128.52.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.30. iRhythm Technologies had a negative net margin of 19.14% and a negative return on equity of 118.83%. The firm had revenue of $164.33 million during the quarter, compared to analysts' expectations of $158.30 million. As a group, equities analysts anticipate that iRhythm Technologies, Inc. will post -1.98 EPS for the current fiscal year.

About iRhythm Technologies

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.